Bolder BioTechnology announced NIAID's option to fund the second year of Contract NIH-BAA-75N93023C00011, focusing on BBT-059's advanced development as a radiation medical countermeasure. The contract aims to complete GMP manufacturing, preclinical safety studies, and enable an Investigational New Drug Application filing with the FDA, totaling $3,079,369.